Cue Biopharma, Inc. (CUE) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 37.66M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $37.66M | (m) | (m) |
| 2026-03-31 | (m) | $32.73M | (m) | (m) |
| 2025-12-31 | (m) | $27.47M | (m) | (m) |
| 2025-09-30 | (m) | $7.10M | (m) | (m) |
| 2025-06-30 | (m) | $8.29M | (m) | (m) |
| 2025-03-31 | (m) | $7.99M | (m) | (m) |
| 2024-12-31 | (m) | $9.29M | (m) | (m) |
| 2024-09-30 | (m) | $9.53M | (m) | (m) |
| 2024-06-30 | (m) | $8.29M | (m) | (m) |
| 2024-03-31 | (m) | $7.02M | (m) | (m) |
| 2023-12-31 | (m) | $5.49M | (m) | (m) |
| 2023-09-30 | (m) | $3.82M | (m) | (m) |
| 2023-06-30 | (m) | $1.79M | (m) | (m) |
| 2023-03-31 | (m) | $432.23K | (m) | (m) |
| 2022-12-31 | (m) | $1.25M | (m) | (m) |
| 2022-09-30 | (m) | $9.35M | (m) | (m) |
| 2022-06-30 | (m) | $11.68M | (m) | (m) |
| 2022-03-31 | (m) | $14.39M | (m) | (m) |
| 2021-12-31 | (m) | $14.94M | (m) | (m) |
| 2021-09-30 | (m) | $7.16M | (m) | (m) |
| 2021-06-30 | (m) | $5.47M | (m) | (m) |
| 2021-03-31 | (m) | $3.81M | (m) | (m) |
| 2020-12-31 | (m) | $3.15M | (m) | (m) |
| 2020-09-30 | (m) | $3.73M | (m) | (m) |
| 2020-06-30 | (m) | $4.01M | (m) | (m) |
| 2020-03-31 | (m) | $3.99M | (m) | (m) |
| 2019-12-31 | (m) | $3.46M | (m) | (m) |
| 2019-09-30 | (m) | $2.74M | (m) | (m) |
| 2019-06-30 | (m) | $2.20M | (m) | (m) |
| 2019-03-31 | (m) | $1.32M | (m) | (m) |
| 2018-12-31 | (m) | $1.14M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |